http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Tsutomu Fujimura,Mitsuyuki Hotta,Takashi Kitahara,Yoshinori Takema 대한약학회 2011 Archives of Pharmacal Research Vol.34 No.6
Although there have been many reports about the relationship between force generation by skeletal muscles and aging, no study has investigated the relationship between contraction forces generated by non-muscle cells and aging. In this study, we examined that relationship using fibroblast populating collagen gels and a contraction force detecting system. Fibroblasts at passages 5 to 7 were used as the young group and those at passages 17 to 19 were used as the aged group. The contraction force induced by thrombin or lysophosphatidic acid significantly decreased with age. The expression of myosin light chain kinase (MLCK) and two types of Rho kinases (Rock-1 and Rock-2) decreased with age, but the expression of Rho A and myosin phosphatase (MPPase) did not change at all. The expression of myosin light chain 20k (MLC_20) depended on the donor fibroblasts. Fibroblasts from young or aged hairless mice showed similar age-dependent results. Taken together, our data suggest that decreased expressions of MLCK and Rho kinase are critical for loss of force generation by fibroblasts with aging, which suggests new mechanisms of functional deficiencies due to aging.
Sumire Mori,Toshihiko Tomita,Kazuki Fujimura,Haruki Asano,Tomohiro Ogawa,Takahisa Yamasaki,Takashi Kondo,Tomoaki Kono,Katsuyuki Tozawa,Tadayuki Oshima,Hirokazu Fukui,Takeshi Kimura,Jiro Watari,Hiroto 대한소화기 기능성질환∙운동학회 2019 Journal of Neurogastroenterology and Motility (JNM Vol.25 No.4
Background/Aims Magnesium oxide (MgO) has been frequently used as a treatment for chronic constipation (CC) since the 1980s in Japan. The aim of this study is to evaluate its therapeutic effects of MgO in Japanese CC patients. Methods We conducted a randomized, double-blind placebo-controlled study. Thirty-four female patients with mild to moderate constipation were randomly assigned to either placebo (n = 17) or MgO group (n = 17) 0.5 g × 3/day for 28 days. Primary endpoint was overall improvement over the 4-week study period. Secondary endpoints were changes from baseline in spontaneous bowel movement (SBM), response rates of complete spontaneous bowel movement (CSBM), stool form, colonic transit time (CTT), abdominal symptom, and quality of life. Results One patient failed to complete the medication regimen and was omitted from analysis: data from 16 placebo and 17 MgO patients were analyzed. The primary endpoint was met by 25.0% of placebo vs 70.6% of MgO group (P = 0.015). MgO significantly improved SBM changes compared to placebo (P = 0.002). However, MgO did not significantly improved response rates of CSBM compared to placebo (P = 0.76). In addition, MgO significantly improved Bristol stool form scale changes (P < 0.001) and significantly improved CTT compared to the placebo group (P < 0.001). MgO significantly improved the Japanese version of the patient assessment of constipation quality of life (P = 0.003). Conclusion Our placebo-controlled study demonstrated that MgO was effective treatment for improving defecation status and shortened CTT in Japanese CC patients with mild to moderate symptoms. Background/Aims Magnesium oxide (MgO) has been frequently used as a treatment for chronic constipation (CC) since the 1980s in Japan. The aim of this study is to evaluate its therapeutic effects of MgO in Japanese CC patients. Methods We conducted a randomized, double-blind placebo-controlled study. Thirty-four female patients with mild to moderate constipation were randomly assigned to either placebo (n = 17) or MgO group (n = 17) 0.5 g × 3/day for 28 days. Primary endpoint was overall improvement over the 4-week study period. Secondary endpoints were changes from baseline in spontaneous bowel movement (SBM), response rates of complete spontaneous bowel movement (CSBM), stool form, colonic transit time (CTT), abdominal symptom, and quality of life. Results One patient failed to complete the medication regimen and was omitted from analysis: data from 16 placebo and 17 MgO patients were analyzed. The primary endpoint was met by 25.0% of placebo vs 70.6% of MgO group (P = 0.015). MgO significantly improved SBM changes compared to placebo (P = 0.002). However, MgO did not significantly improved response rates of CSBM compared to placebo (P = 0.76). In addition, MgO significantly improved Bristol stool form scale changes (P < 0.001) and significantly improved CTT compared to the placebo group (P < 0.001). MgO significantly improved the Japanese version of the patient assessment of constipation quality of life (P = 0.003). Conclusion Our placebo-controlled study demonstrated that MgO was effective treatment for improving defecation status and shortened CTT in Japanese CC patients with mild to moderate symptoms.
Estimation of Radiocesium In/out Flows in Paddy Fields in Fukushima, Japan
Seiko Yoshikawa,Eguchi Sadao,Itahashi Sunao,Igura Masato,Nobuharu Kihou,Shigeto Fujimura,Takashi Saito,Hideshi Fujihara,Shinichiro Mishima,Kazunori Kohyama,Noriko Yamaguchi,Ohkoshi Satoru 한국토양비료학회 2014 한국토양비료학회 학술발표회 초록집 Vol.2014 No.6